Does Revolution Medicines' pancreatic cancer drug have even greater potential?
statnews.com • • health
Key Points:
- Revolution Medicines’ drug daraxonrasib shows strong potential for approval in treating metastatic pancreatic cancer after chemotherapy failure.
- The primary factor delaying approval is the speed of the company’s submission to the FDA.
- Upon submission, daraxonrasib is expected to receive rapid clearance and establish itself as the new standard of care in second-line treatment.